Helmy Eltoukhy is a prominent figure in the biotechnology industry, serving as the Chairman and Co-Chief Executive Officer at Guardant Health Inc. Born and raised in Cairo, Egypt, Eltoukhy moved to the United States to pursue his education and career. He holds a Ph.D. in electrical engineering from Stanford University, where his research focused on developing novel DNA sequencing technologies. This foundational work laid the groundwork for his future endeavors in the genomics and oncology fields. Eltoukhy co-founded Guardant Health in 2012 with AmirAli Talasaz, aiming to revolutionize cancer care through non-invasive liquid biopsy testing. Under his leadership, Guardant Health has grown into a leading precision oncology company, offering advanced diagnostic tools that help clinicians detect cancer early, monitor treatment response, and identify actionable genetic mutations. One of the company's flagship products, Guardant360, has been widely adopted in clinical settings, enabling personalized treatment plans for cancer patients. Eltoukhy's strategic vision and commitment to innovation have been instrumental in securing multiple patents and driving the company's expansion. As Chairman and Co-CEO, Helmy Eltoukhy continues to steer Guardant Health towards new frontiers in cancer diagnostics and treatment. His leadership has not only propelled the company to achieve significant milestones, such as a successful IPO in 2018, but also fostered a culture of scientific excellence and patient-centered care. Eltoukhy's contributions to the field have been recognized with numerous awards, including being named one of the "Top 100 Young Innovators" by Goldman Sachs. His ongoing efforts are focused on advancing Guardant Health's mission to conquer cancer through cutting-edge technology and research.